The Team


Guy Yachin, BSc., MBA

Co-Founder & CEO
Entrepreneur and CEO of multiple biomedical companies; raised over $80MM as CEO and Co-founder of Chiasma (Nasdaq:CHMA) and MGVS, which he led through a mega-deal with Teva Pharmaceuticals; Has been an active board member in Orgenesis (Nasdaq:ORGS), Enzymotec (Nasdaq:ENZY), Remon Technologies (acquired by Boston Scientific), Serpin Pharma and others.

Dr. Ethan Ludmir, M.D.

Medical Adviser, PI

Assistant Professor, Dept. of Gastrointestinal Radiation Oncology and Department of Biostatistics, MD Anderson Cancer Center, Houston, TX. Dr. Ludmir has considerable expertise in trial design in radiation oncology and in biostatistical methodology.

Dr. Michael Shtein, Ph.D, MBA

Co-Founder & Executive Chairman
Entrepreneur with over 15 years of Managerial and R&D Experience, Dr. Shtein is an expert in commercializing an academia concepts to products and is a cofounder of several biomed companies.

Jessica Molkentine

Director of Clinical Development

Jessica serves as the company’s Director of Clinical Development. In addition to my role with Xerient, I’m currently an Associate Scientist at UT MD Anderson Cancer Center with 19 years of experience in preclinical and translational cancer research and a background in radiation oncology.

Board of directors

Guy Hoffman


30-year investment and fund-manager veteran with direct experience in capital formation. Managing Member of NewTech Investment Holdings, an advanced materials and Bio/MedTech investment vehicle. Former co-founder, partner and investment committee member of Chambers Energy Capital, an energy investment fund for more than a decade. Board member of Nanorobotics, Ltd., Cobionix Corporation and Xerient Pharma Ltd. among others.

Mr. Eyal Lifschitz


Eyal Lifschitz is a business founder and entrepreneur with years of experience establishing and managing medical technology companies and their business development efforts. Eyal was involved as a founder and a manger in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. and as a director of Given Imaging (NASDAQ: GIVN).

He holds an LLB from the Academic Center for Law and Science.

Mr. Doron Eldar


Result-focused entrepreneur with more than a decade of experience in senior leadership roles and is currently a Melbourne-based partner at venture capital fund SIBF.
Mr Eldar has extensive experience scaling innovative tech companies globally, formulating effective go-to-market strategies and driving market awareness for private and public tech companies.
Doron is also a venture partner at Oxen9 and a Director at Dotz Nano (ASX:DTZ), Electric Global, Livia and others.

To be announced

Proposed Chairman of the Board

Scientific team and Advisors

Dr. Zan Fleming, M.D.

Regulatory Advisor
President and CEO of Kinexium, LLC, a global strategic organization focused on regulatory strategies and drug development. He sits on clinical advisory boards of major pharma and biotech companies and is a sought-after expert and spokesperson. For 12 years he served as reviewer and supervisory medical officer at the FDA. As the head of the metabolic group he led the landmark approvals of metformin, the first statin, human insulin analog and more.  Dr. Fleming received his MD and internal medicine training from Emory University, followed by training at Vanderbilt and the NIH.

Danit Licht

Formulation Director

Expert in Pharmaceutical R&D for more than 30 years, Responsible the development of known products. Served as Associate Director in the Innovative Pharma R&D of TEVA, Taro Pharmaceutical and various pharmaceutical firms.

Danit Holds B.F.E&B (Bachelor of Food Engineering and Biotechnology) from the Technion Institute, Haifa, and M.Sc in Pharmaceutical Chemistry at the Bar-Ilan University and B.Sc in Chemistry (especially in Organic Chemistry) at the Tel-Aviv University, Israel. Danit Issued dozens of patents worldwide and published articles.

Mr. Ofer Doron

Preclinical Director

Mr. Doron was the Manging Director of Lahav Research Institute (the largest large animals CRO in Israel) for 13 years. He was involved in the development of many medical devices and Pharmaceutical products. Mr. Doron serves today as a cosultant to various companies, he joined Xerient Pharma in 2020.

Prof. Daniel D. Von Hoff M.D.

Chief Medical Advisor

Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. His clinical trial work has led   to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts

Prof. Cullen Taniguchi, M.D,
1976 - 2023


Board-certified radiation oncologist he was an Assistant Professor in Radiation Oncology at MD Anderson Cancer Center, specializing in treating gastrointestinal malignancies, with a clinical focus on unresectable pancreatic cancer.

For more information
please leave your details:


3730 Kirby Drive, Suite 1200, Houston, Texas 77098